GlassScriptPhysician profile
Marian E Northington
NPI 1841220589
$18,387.98
in general payments reported to CMS, 2019-2025
32 companies · $2,733 in 2025
The $2,733 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,191 · 2020: $374 · 2021: $1,168 · 2022: $1,207 · 2023: $2,706 · 2024: $4,011 · 2025: $2,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,406 · Food and Beverage: $4,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,406.25 |
| Food and Beverage | $4,042.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,087.07 | 2021-2025 | |
| Allergan, INC. | $6,509.55 | 2019-2022 | |
| Merz North America, INC. | $673.96 | 2019-2020 | |
| Genzyme Corporation | $369.63 | 2019-2024 | |
| Dermavant Sciences, INC. | $355.18 | 2023-2024 | Vtama |
| Leo Pharma INC. | $284.90 | 2019-2025 | Adbry |
| Incyte Corporation | $278.56 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $249.70 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $189.84 | 2019-2024 | |
| Organon LLC | $168.02 | 2025 | Vtama, Nexplanon |
| Arcutis Biotherapeutics, INC. | $146.14 | 2025 | Zoryve |
| Pfizer INC. | $139.18 | 2019-2023 | |
| Lilly USA, LLC | $134.28 | 2019-2024 | Taltz |
| Regeneron Healthcare Solutions, INC. | $128.49 | 2022-2025 | Dupixent |
| Galderma Laboratories, L.P. | $127.37 | 2019-2025 | Nemluvio, Aklief, Epsolay |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $100.54 | 2019-2023 | Klisyri |
| Vyne Pharmaceuticals INC. | $67.74 | 2020-2021 | |
| Janssen Biotech, INC. | $63.35 | 2020-2024 | Tremfya |
| Verrica Pharmaceuticals INC. | $33.45 | 2023-2024 | Ycanth |
| Strata Skin Sciences, INC. | $32.98 | 2020-2022 | |
| Epi Health, LLC | $29.47 | 2021-2022 | |
| Nabriva Therapeutics, Plc | $29.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $27.15 | 2024 | |
| Dermira, INC. | $26.37 | 2019 | |
| Genentech USA, INC. | $24.84 | 2019 | |
| Merck Sharp & Dohme LLC | $22.54 | 2019 | |
| Mission Pharmacal Company | $17.93 | 2019 | |
| Boston Scientific Corporation | $15.58 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $15.10 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.86 | 2025 | Cabtreo, Jublia, Siliq |
| Paratek Pharmaceuticals, INC. | $13.20 | 2024 | Nuzyra |
| Fresenius Kabi USA, LLC | $13.01 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marian Northington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.